In this episode, FLASCO leaders Maen Hussein, MD, and Wassim McHayleh, MD join the discussion to explore the evolving role of ESR1 mutation testing in metastatic breast cancer. They highlight how these mutations, both acquired and intrinsic, shape treatment decisions and influence patient outcomes. Drawing from real-world data and insights from FLASCO’s statewide survey, the conversation offers practical perspectives on current testing practices, clinical implications, and opportunities to improve personalized care for patients with hormone receptor–positive breast cancer.

This content has been created independently and solely by FLASCO. FLASCO would like to recognize our Elite Corporate Partner, Stemline Therapeutics, a Menarini company, for their partnership with FLASCO in advancing education and collaboration in oncology.